Assessment of the cardiac safety of fampridine-SR sustained-release tablets in a thorough QT/QTc evaluation at therapeutic and supratherapeutic doses in healthy individuals
Authors:
- Barrie MarchBMBarrie March
- Tara CardiTCTara Cardi
- 23 October 2009
- journal article
- research article
- Published by Informa Healthcare in Expert Opinion on Investigational Drugs
- Vol. 18 (12) , 1807-1815
Abstract
Objective: To characterize the effects of a sustained-release formulation of fampridine (fampridine-SR) on QT interval in healthy subjects. Methods: In a double-blind, double-dummy trial, healthy subjects were randomized to 5 days treatment with fampridine-SR at therapeutic (10 mg twice daily) or supratherapeutic (30 mg twice daily) doses, placebo or moxifloxacin (400 mg on treatment day 5). Digital 12-lead electrocardiograms were recorded before treatment and on day 5; blood samples determined fampridine concentrations. Central tendency analysis determined whether the upper limit of the CI for the QT (individual-corrected QT; QTcI) interval change exceeded 10 ms. Outlier analysis determined new-onset QT (corrected QT; QTc) intervals; maximum change in QTc from baseline of 30 – 60 ms and maximum change from baseline ≥ 60 ms. The relationship between pharmacokinetic parameters and QTcI values is explored. Results: Moxifloxacin was associated with a QTcI interval increase > 5 ms at 7 time points; no increas...Keywords
This publication has 24 references indexed in Scilit:
- Effects of 4‐Aminopyridine on Cloned hERG Channels Expressed in Mammalian CellsArchives of Drug Information, 2009
- Dose comparison trial of sustained-release fampridine in multiple sclerosisNeurology, 2008
- The plateau outward current in canine ventricle, sensitive to 4‐aminopyridine, is a constitutive contributor to ventricular repolarizationBritish Journal of Pharmacology, 2007
- Potassium channel blockers in multiple sclerosis: Neuronal Kv channels and effects of symptomatic treatmentPharmacology & Therapeutics, 2006
- Inhibition of HERG K+ Current and Prolongation of the Guinea‐Pig Ventricular Action Potential by 4‐AminopyridineThe Journal of Physiology, 2003
- Molecular basis of functional voltage‐gated K+ channel diversity in the mammalian myocardiumThe Journal of Physiology, 2000
- Repolarizing K+ currents in rabbit heart Purkinje cellsThe Journal of Physiology, 1998
- A mechanistic link between an inherited and an acquird cardiac arrthytmia: HERG encodes the IKr potassium channelCell, 1995
- Gating-dependent mechanism of 4-aminopyridine block in two related potassium channels.Journal of General Physiology, 1993
- 4-Aminopyridine in Patients with Multiple SclerosisClinical Neuropharmacology, 1993